Skip to main content
Premium Trial:

Request an Annual Quote

Poniard to Use AltheaDx Platform to ID Molecular Signatures

NEW YORK (GenomeWeb News) – Poniard Pharmaceuticals said today that it will use AltheaDx’s Express Pathway program to identify molecular signatures that may be correlated to platinum resistance.
The South San Francisco, Calif.-based biopharmaceutical firm is developing platinum-based therapies for cancer and has produced a new agent designed to overcome platinum resistance. It plans to use AltheaDx’s high-throughput gene expression platform to develop molecular signatures of platinum resistance that may enable the prediction of clinical response to the new drug — called picoplatin — and improve patient outcomes.
Terms of the collaboration were not disclosed.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.